Villers-Cotterêts (FR)
{name}
{subtitle}
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~50 mi. (Bobigny, France, +158 more cities)
facility
Hopital Avicenne ( Site 0803)
condition
Non-Small Cell Lung Carcinoma
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~50 mi. (Bobigny, France, +122 more cities)
facility
Hopital Avicenne ( Site 1106)
condition
Small Cell Lung Carcinoma
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
~50 mi. (Bobigny, France, +197 more cities)
facility
Hopital Avicenne - APHP /ID# 215152
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
condition
Acute Myeloid Leukemia
drug
azacitidine, +1 more drug
drug type
chemotherapy
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
city
~50 mi. (Bobigny, France, +142 more cities)
facility
Hopital Avicenne - Hématologie Clinique
biomarker
del(11)(q10), +27 more biomarkers
condition
Myelofibrosis
drug
imetelstat, +1 more drug
drug type
targeted therapy
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
city
~50 mi. (Bobigny, France, +165 more cities)
facility
Hopital Avicenne - APHP /ID# 221286
biomarker
del(11)(q10), +27 more biomarkers
condition
Myelofibrosis
drug
navitoclax, +1 more drug
drug type
targeted therapy
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
city
~50 mi. (Paris Campagne, France, +55 more cities)
facility
Hôpital Universitaire Pitié Salpêtrière (Adults only)
condition
Post-Transplant Lymphoproliferative Disorder
drug
tabelecleucel
drug type
cellular therapy, +1 more type